{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:00:25Z","timestamp":1772492425590,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"DOI":"10.7759\/cureus.104564","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T22:20:19Z","timestamp":1772490019000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond Glucose Control: A Comprehensive Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure, Chronic Kidney Disease, and Nonalcoholic Fatty Liver Disease"],"prefix":"10.7759","author":[{"given":"Alexander R","family":"Sosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C","family":"Sosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","unstructured":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022, 102.S1-S127. 10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12505","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions","volume":"6","author":"Lan NS","year":"2019","unstructured":"Lan NS, Fegan PG, Yeap BB, Dwivedi G. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Fail. 2019, 6:927-35. 10.1002\/ehf2.12505","journal-title":"ESC Heart Fail"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington WG","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al.. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023, 388:117-27. 10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon CP","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al.. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020, 383:1425-35. 10.1056\/NEJMoa2004967","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay MS","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, et al.. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. 2018, 41:1801-8. 10.2337\/dc18-0165","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108610","article-title":"Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"37","author":"Shi M","year":"2023","unstructured":"Shi M, Zhang H, Wang W, et al.. Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease. J Diabetes Complications. 2023, 37:108610. 10.1016\/j.jdiacomp.2023.108610","journal-title":"J Diabetes Complications"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20176671","article-title":"Immunomodulatory effects of SGLT2 inhibitors-targeting inflammation and oxidative stress in aging","volume":"20","author":"Sch\u00f6nberger E","year":"2023","unstructured":"Sch\u00f6nberger E, Mihaljevi\u0107 V, Steiner K, et al.. Immunomodulatory effects of SGLT2 inhibitors-targeting inflammation and oxidative stress in aging. Int J Environ Res Public Health. 2023, 20:10.3390\/ijerph20176671","journal-title":"Int J Environ Res Public Health"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2022.11.1.1","article-title":"SGLT2 inhibitors and ketone metabolism in heart failure","volume":"11","author":"Saucedo-Orozco H","year":"2022","unstructured":"Saucedo-Orozco H, Voorrips SN, Yurista SR, de Boer RA, Westenbrink BD. SGLT2 inhibitors and ketone metabolism in heart failure. J Lipid Atheroscler. 2022, 11:1-19. 10.12997\/jla.2022.11.1.1","journal-title":"J Lipid Atheroscler"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney DZ","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, et al.. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014, 129:587-97. 10.1161\/CIRCULATIONAHA.113.005081","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon SD","year":"2022","unstructured":"Solomon SD, McMurray JJ, Claggett B, et al.. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022, 387:1089-98. 10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022, 145:e895-e1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh TA","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023, 44:3627-39. 10.1093\/eurheartj\/ehad195","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology solution set oversight committee","volume":"77","author":"Maddox TM","year":"2021","unstructured":"Maddox TM, Januzzi JL Jr, Allen LA, et al.. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol. 2021, 77:772-810. 10.1016\/j.jacc.2020.11.022","journal-title":"J Am Coll Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin J","year":"2025","unstructured":"Lin J, Huang Y, Xu B, et al.. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025, 389:e083735. 10.1136\/bmj-2024-083735","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al.. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023, 77:1797-835. 10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06196-3","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary","volume":"67","year":"2024","unstructured":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). executive summary. Diabetologia. 2024, 67:2375-92. 10.1007\/s00125-024-06196-3","journal-title":"Diabetologia"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)","volume":"136","author":"Kosiborod M","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, et al.. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017, 136:249-59. 10.1161\/CIRCULATIONAHA.117.029190","journal-title":"Circulation"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06126-3","article-title":"Effectiveness and safety of empagliflozin: final results from the EMPRISE study","volume":"67","author":"Htoo PT","year":"2024","unstructured":"Htoo PT, Tesfaye H, Schneeweiss S, et al.. Effectiveness and safety of empagliflozin: final results from the EMPRISE study. Diabetologia. 2024, 67:1328-42. 10.1007\/s00125-024-06126-3","journal-title":"Diabetologia"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda P","year":"2018","unstructured":"Ueda P, Svanstr\u00f6m H, Melbye M, et al.. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018, 363:k4365. 10.1136\/bmj.k4365","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S011","article-title":"Chronic kidney disease and risk management: standards of care in diabetes-2025","volume":"48","year":"2025","unstructured":"Chronic kidney disease and risk management. standards of care in diabetes-2025. Diabetes Care. 2025, 48:S239-51. 10.2337\/dc25-S011","journal-title":"Diabetes Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters AL","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015, 38:1687-93. 10.2337\/dc15-0843","journal-title":"Diabetes Care"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009099","article-title":"Out-of-pocket costs for SGLT-2 (sodium-glucose transport protein-2) inhibitors in the United States","volume":"15","author":"Aggarwal R","year":"2022","unstructured":"Aggarwal R, Vaduganathan M, Chiu N, Bhatt DL. Out-of-pocket costs for SGLT-2 (sodium-glucose transport protein-2) inhibitors in the United States. Circ Heart Fail. 2022, 15:e009099. 10.1161\/CIRCHEARTFAILURE.121.009099","journal-title":"Circ Heart Fail"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.4205","article-title":"Coverage, formulary restrictions, and affordability of sodium-glucose cotransporter 2 inhibitors by US insurance plan types","volume":"2","author":"Tummalapalli SL","year":"2021","unstructured":"Tummalapalli SL, Montealegre JL, Warnock N, Green M, Ibrahim SA, Estrella MM. Coverage, formulary restrictions, and affordability of sodium-glucose cotransporter 2 inhibitors by US insurance plan types. JAMA Health Forum. 2021, 2:e214205. 10.1001\/jamahealthforum.2021.4205","journal-title":"JAMA Health Forum"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0213","article-title":"Adoption of new glucose-lowering medications in the U.S.-the case of SGLT2 inhibitors: nationwide cohort study","volume":"21","author":"McCoy RG","year":"2019","unstructured":"McCoy RG, Dykhoff HJ, Sangaralingham L, Ross JS, Karaca-Mandic P, Montori VM, Shah ND. Adoption of new glucose-lowering medications in the U.S.-the case of SGLT2 inhibitors: nationwide cohort study. Diabetes Technol Ther. 2019, 21:702-12. 10.1089\/dia.2019.0213","journal-title":"Diabetes Technol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/344697-beyond-glucose-control-a-comprehensive-review-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-in-heart-failure-chronic-kidney-disease-and-nonalcoholic-fatty-liver-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T22:20:19Z","timestamp":1772490019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/344697-beyond-glucose-control-a-comprehensive-review-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-in-heart-failure-chronic-kidney-disease-and-nonalcoholic-fatty-liver-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.104564","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}